Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02674854 · ClinicalTrials.gov registry record · Phase 3
Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
A Phase 3 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 750
- Enrollment target
NCT02674854: Completed Phase 3 study, sponsored by Aerie Pharmaceuticals.
NCT02674854 is a Phase 3 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 750 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02674854, a Phase 3 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 750 participants
- Enrollment target
Study Summary
To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to netarsudil (AR-13324) ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005%
Primary Outcome
Mean intraocular pressure(IOP) at 08:00, 10:00 and 16:00 hours, at Day 15, Day 43 and Day 90, as measured by Goldmann applanation tonometry.
Interventions
- DRUG PG324 Ophthalmic Solution 0.02%/0.005%
- DRUG Netarsudil (AR-13324) ophthalmic solution 0.02%
- DRUG Latanoprost ophthalmic solution 0.005%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-03 |
| Phase | Phase 3 |
What the finished NCT02674854 record still lists
NCT02674854 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which PG324 Ophthalmic Solution 0.02%/0.005% is the first listed.
NCT02674854 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02674854 about?
NCT02674854 is a clinical study titled "Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension". To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to netarsudil (AR-13324) ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005%
What is the current status of trial NCT02674854?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 2016-02. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02674854?
The interventions under investigation include: PG324 Ophthalmic Solution 0.02%/0.005% (DRUG), Netarsudil (AR-13324) ophthalmic solution 0.02% (DRUG), Latanoprost ophthalmic solution 0.005% (DRUG).
Who is sponsoring clinical trial NCT02674854?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02674854's enrollment target sits among peer trials
750 464th of 2000 higher than 1,529 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia